Clinical Outcomes of Topical Recombinant Human Epidermal Growth Factor in Diabetic Foot Ulcers: A Retrospective Single-Centre Cohort Study.
- 1Department of General Surgery, Chronic Wound Unit, Mersin City Training and Research Hospital, Mersin, Türkiye.
Abstract
To describe recorded outcomes of diabetic foot ulcers treated with topical recombinant human epidermal growth factor as part of routine care. This retrospective, single-centre cohort study included 150 consecutive patients receiving Regen-D 150 without a control group. We added treatment when standard care did not produce adequate granulation. We defined the primary outcome as complete healing of the index ulcer without amputation. The primary outcome occurred in 101/150 patients (67.3%; 95% confidence interval 59.5-74.3). Sixteen underwent amputation (11 minor, 5 major), 27 had ongoing status at last follow-up, three died and three were lost to follow-up. Ongoing status included open wounds and closed but unconfirmed wounds. Median recorded time to healing was 13 weeks (interquartile range 10-16). Wound area analyses were exploratory because of unresolved timing inconsistencies. We could not confirm healing for all recorded healings. About two-thirds had recorded healing without amputation during variable follow-up. These uncontrolled, descriptive findings do not establish efficacy, superiority or amputation prevention.
Related
- Clinical Outcomes of Patients Hospitalized With Diabetic Foot Ulcer at a Tertiary Hospital in Ethiopia: A 5‐Year Retrospective Audit
- Early clinical outcomes after switching to faricimab in previously treated diabetic macular edema
- Antialbuminuric Effect of Dapagliflozin Correlates With Urinary Epidermal Growth Factor in Real-World Patients With Diabetic Kidney Disease
- Acute triggers and long-term postpartum outcomes of diabetic ketoacidosis in pregnancy: a 7-case retrospective series.
- HADS-Assessed Anxiety/Depression Status and Ocular Outcomes in Vision-Threatening Diabetic Retinopathy: A Multicenter Retrospective Cohort Study.
BibTeX
@article{soyer2026clinical,
title = {{Clinical Outcomes of Topical Recombinant Human Epidermal Growth Factor in Diabetic Foot Ulcers: A Retrospective Single-Centre Cohort Study.}},
author = {Haci Vural Soyer and Sinan Aslan and Samed Sayar and Guvenc Diner},
journal = {International wound journal},
year = {2026},
month = oct,
doi = {10.1111/iwj.71076},
url = {https://europepmc.org/article/MED/42906895},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Clinical Outcomes of Topical Recombinant Human Epidermal Growth Factor in Diabetic Foot Ulcers: A Retrospective Single-Centre Cohort Study.
AU - Haci Vural Soyer
AU - Sinan Aslan
AU - Samed Sayar
AU - Guvenc Diner
PY - 2026
DA - 2026/10/01
JO - International wound journal
DO - 10.1111/iwj.71076
UR - https://europepmc.org/article/MED/42906895
AB - To describe recorded outcomes of diabetic foot ulcers treated with topical recombinant human epidermal growth factor as part of routine care. This retrospective, single-centre cohort study included 150 consecutive patients receiving Regen-D 150 without a control group. We added treatment when standard care did not produce adequate granulation. We defined the primary outcome as complete healing of the index ulcer without amputation. The primary outcome occurred in 101/150 patients (67.3%; 95% confidence interval 59.5-74.3). Sixteen underwent amputation (11 minor, 5 major), 27 had ongoing status at last follow-up, three died and three were lost to follow-up. Ongoing status included open wounds and closed but unconfirmed wounds. Median recorded time to healing was 13 weeks (interquartile range 10-16). Wound area analyses were exploratory because of unresolved timing inconsistencies. We could not confirm healing for all recorded healings. About two-thirds had recorded healing without amputation during variable follow-up. These uncontrolled, descriptive findings do not establish efficacy, superiority or amputation prevention.
SN - 1742-4801
SN - 1742-481X
ER -